ClinicalTrials.gg

Program

camrelizumab

Also written as “SHR-1210”, “Camrelizumab” and “camrelizumab + famitinib”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma, Hepatocellular · Stomach Neoplasms · Triple Negative Breast Neoplasms · Nasopharyngeal Carcinoma, led by 7 companies.

Furthest: phase 3, since Mar 28, 201754 company-led studies, 11 open or runningNext primary completion: Dec 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine475 open or runningphase 3since Mar 28, 2017Jun 26, 2015none ahead
HRYZ Biotech21 open or runningphase 1since Dec 27, 2017Dec 27, 2017none ahead
CNBG-Virogin Biotech (Shanghai)11 open or runningphase 2since Oct 16, 2023Oct 16, 2023none ahead
CrystalGenomics11 open or runningphase 2since Mar 30, 2023Mar 30, 2023none ahead
GrandPharma (China)11 open or runningphase 2since Aug 13, 2025Aug 13, 2025Dec 30, 2027phase 2 · NCT07334483
Guangzhou Virotech Pharmaceutical11 open or runningphase 3since May 8, 2026May 8, 2026Dec 31, 2028phase 3 · NCT07589244
HUTCHMED11 open or runningphase 3since Mar 26, 2024Mar 26, 2024May 31, 2028phase 3 · NCT06361888

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 39 studies since Jun 26, 2015.

  1. Nov 5, 20202 phase 3 studiesJiangsu HengRui Medicine · NCT04619433, NCT04639180
  2. Dec 7, 2020Phase 2 study in RecurrenceJiangsu HengRui Medicine · NCT04680988 · 194 enrolled · China
  3. May 26, 2021Phase 3 study in Uterine Cervical NeoplasmsJiangsu HengRui Medicine · NCT04906993 · 443 enrolled · China
  4. Jul 15, 2021Phase 3 study in Advanced Hepatocellular Carcinoma (HCC)Jiangsu HengRui Medicine · NCT04985136 · 1 enrolled · China
  5. Sep 1, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungJiangsu HengRui Medicine · NCT05042375 · 450 planned · China
  6. Oct 22, 2021Phase 3 study in Advanced NSCLCJiangsu HengRui Medicine · NCT05106335 · 1 enrolled · China
  7. Jan 28, 2022Phase 2 study in Advanced Solid TumorsJiangsu HengRui Medicine · NCT05214976 · 64 enrolled · China
  8. Apr 2, 2022Phase 3 study in Carcinoma, HepatocellularJiangsu HengRui Medicine · NCT05320692 · 423 enrolled · China
  9. Mar 13, 2023Phase 1 study in Advanced TumorsJiangsu HengRui Medicine · NCT05799183 · 12 enrolled · China
  10. Mar 30, 2023CrystalGenomics's first study: phase 2 study in Non Squamous Non Small Cell Lung CancerNew to CrystalGenomicsCrystalGenomics · NCT05841472 · 60 planned · Korea, Republic of
  11. Oct 16, 2023CNBG-Virogin Biotech (Shanghai)'s first study: phase 2 study in Carcinoma, HepatocellularNew to CNBG-Virogin Biotech (Shanghai)CNBG-Virogin Biotech (Shanghai) · NCT06124001 · 36 planned
  12. Mar 26, 2024HUTCHMED's first study: phase 3 study in Pancreatic NeoplasmsNew to HUTCHMEDHUTCHMED · NCT06361888 · 502 planned · China
  13. Aug 13, 2025GrandPharma (China)'s first study: phase 2 study in HCCNew to GrandPharma (China)GrandPharma (China) · NCT07334483 · 120 planned · China
  14. May 8, 2026Guangzhou Virotech Pharmaceutical's first study: phase 3 study in HCCNew to Guangzhou Virotech PharmaceuticalGuangzhou Virotech Pharmaceutical · NCT07589244 · 66 planned · China

Ahead

  1. Dec 30, 2027Primary completion: phase 2 study in HCCGrandPharma (China) · NCT07334483
  2. May 31, 2028Primary completion: phase 3 study in Pancreatic NeoplasmsHUTCHMED · NCT06361888
  3. Dec 31, 2028Primary completion: phase 3 study in HCCGuangzhou Virotech Pharmaceutical · NCT07589244

TargetBeta

PDCD1 →read by rule
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 54 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07589244HCC · China3RecruitingGuangzhou Virotech PharmaceuticalDec 31, 202866
NCT07334483HCC · China2RecruitingGrandPharma (China)Dec 30, 2027120
NCT06361888Pancreatic Neoplasms · China3RecruitingHUTCHMEDMay 31, 2028502
NCT06124001Carcinoma, Hepatocellular2Not yet recruitingCNBG-Virogin Biotech (Shanghai)Dec 30, 202536
NCT05841472Non Squamous Non Small Cell Lung Cancer · Korea, Republic of2RecruitingCrystalGenomicsAug 202660
NCT05799183Advanced Tumors · China1TerminatedJiangsu HengRui MedicineOct 12, 202312
NCT05320692Carcinoma, Hepatocellular · China3Active, not recruitingJiangsu HengRui MedicineJul 30, 2026423
NCT05214976Advanced Solid Tumors · China2UNKNOWNJiangsu HengRui MedicineJan 31, 202364
NCT05106335Advanced NSCLC · China3TerminatedJiangsu HengRui MedicineMay 11, 20221
NCT05042375Carcinoma, Non-Small-Cell Lung · China3RecruitingJiangsu HengRui MedicineDec 31, 2023450
NCT04985136Advanced Hepatocellular Carcinoma (HCC) · China3TerminatedJiangsu HengRui MedicineDec 29, 20211
NCT04906993Uterine Cervical Neoplasms · China3Active, not recruitingJiangsu HengRui MedicineJun 10, 2025443
NCT04680988Recurrence · China2CompletedJiangsu HengRui MedicineJul 7, 2025194
NCT04639180Carcinoma, Hepatocellular · China3Active, not recruitingJiangsu HengRui MedicineJul 31, 2026687
NCT04619433Non-squamous Non-small-cell Lung Cancer · China3TerminatedJiangsu HengRui MedicineAug 16, 202548
NCT04613674Triple Negative Breast Neoplasms · China3CompletedJiangsu HengRui MedicineSep 14, 2023441
NCT04426955Esophageal Neoplasms · China3UNKNOWNJiangsu HengRui MedicineDec 2022396
NCT04346381Solid Tumor · China2CompletedJiangsu HengRui MedicineJun 22, 2022233
NCT04342936Classical Hodgkin Lymphoma · China3UNKNOWNJiangsu HengRui MedicineAug 1, 202356
NCT04342910Stomach Neoplasms · China3RecruitingJiangsu HengRui MedicineApr 1, 2026550
NCT04335006Breast Neoplasms · China3TerminatedJiangsu HengRui MedicineApr 14, 202380
NCT04203485PD-L1 Positive Non-small Cell Lung Cancer3UNKNOWNJiangsu HengRui MedicineMar 31, 2022762
NCT04074564Sarcoma · ChinaEarly 1RecruitingHRYZ BiotechAug 7, 202460
NCT03945604Triple Negative Breast Neoplasms · China1CompletedJiangsu HengRui MedicineFeb 9, 202132
NCT03813784Stomach Neoplasms · China3CompletedJiangsu HengRui MedicineJun 7, 2023885
NCT03777124Carcinoma, Non-Small-Cell Lung · China2TerminatedJiangsu HengRui MedicineJun 29, 202325
NCT03764293Neoplasm Metastasis · United States, Belgium, China and more3CompletedJiangsu HengRui MedicineFeb 8, 2022543
NCT03827837Carcinoma, Renal Cell · China2UNKNOWNJiangsu HengRui MedicineDec 2022265
NCT03711279Sarcoma · China2TerminatedJiangsu HengRui MedicineJun 21, 202199
NCT03707509Nasopharyngeal Carcinoma · China3UNKNOWNJiangsu HengRui MedicineAug 1, 2021263
NCT03691090Advanced Esophageal Cancer · China3CompletedJiangsu HengRui MedicineOct 30, 2020596
NCT03668496Lung Neoplasms · China3UNKNOWNJiangsu HengRui MedicineNov 6, 2020390
NCT03666728Lung Neoplasms · China2TerminatedJiangsu HengRui MedicineMar 11, 20205
NCT03645876Colorectal Neoplasms · China2TerminatedJiangsu HengRui MedicineApr 18, 201912
NCT03605706Advanced Hepatocellular Carcinoma · China3UNKNOWNJiangsu HengRui MedicineFeb 2023396
NCT03558191Nasopharyngeal Carcinoma · China2CompletedJiangsu HengRui MedicineDec 30, 2021156
NCT03491631Neoplasms · China1UNKNOWNJiangsu HengRui MedicineJun 202323
NCT03472365Stomach Neoplasms · China2CompletedJiangsu HengRui MedicineNov 25, 202067
NCT03463876Carcinoma, Hepatocellular · China2CompletedJiangsu HengRui MedicineMar 10, 2021190
NCT03417895Small Cell Lung Carcinoma · China2CompletedJiangsu HengRui MedicineAug 4, 202159
NCT03393416Advanced Gastric Cancer · China1UNKNOWNHRYZ BiotechJul 202028
NCT03363555Lymphoma, Extranodal NK-T-Cell · China2UNKNOWNJiangsu HengRui MedicineJun 30, 201997
NCT03182673Solid Tumor · China1TerminatedJiangsu HengRui MedicineJun 12, 201931
NCT03155425Hodgkin Disease · China2CompletedJiangsu HengRui MedicineAug 31, 202075
NCT03134872Lung Neoplasms · China3CompletedJiangsu HengRui MedicineJul 27, 2019419
NCT03121716Nasopharyngeal Carcinoma · China1CompletedJiangsu HengRui MedicineJul 28, 202023
NCT03099382Esophageal Neoplasms · China3CompletedJiangsu HengRui MedicineMay 6, 2019457
NCT03085069Lung Neoplasms · China2UNKNOWNJiangsu HengRui MedicineAug 20, 2020146
NCT03083041Carcinoma, Non-Small-Cell Lung · China2CompletedJiangsu HengRui MedicineApr 22, 2022210
NCT02989922Hepatocellular Carcinoma Non-Resectable · China2CompletedJiangsu HengRui MedicineMar 3, 2020220
NCT02742935Breast Neoplasms · China1CompletedJiangsu HengRui MedicineMay 6, 201999
NCT02738489Advanced Melanoma · China1CompletedJiangsu HengRui MedicineJan 8, 202036
NCT02721589Advanced Solid Tumors · China1CompletedJiangsu HengRui MedicineNov 17, 2019126
NCT02492789Hematologic Neoplasms · Australia1CompletedJiangsu HengRui MedicineMar 1, 201949

How it is read

Names in the registry

  • “SHR-1210”, 25 entries
  • “Camrelizumab”, 6 entries
  • “camrelizumab”, 4 entries
  • “camrelizumab + famitinib”, 2 entries
  • “VRT106 in combination with camrelizumab and apatinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.